Close to a decade after Eli Lilly killed it, Jeffrey Bluestone's 'breakthrough' drug is back and being steered to the FDA
The diabetes drug teplizumab has taken another step forward in the long, painfully slow trek out of the R&D wilderness. And the next stop could be the FDA.
Banished to the shelves 9 years ago at Eli Lilly, the drug from the lab of UCSF scientist and Parker Institute chief Jeffrey Bluestone has now won the FDA’s breakthrough therapy designation — an elite regulatory status that should speed its way into the hands of reviewers.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.